Association of polycythemia with outcomes of acute decompensated heart failure: A matched and weighted cohort analysis

红细胞增多症与急性失代偿性心力衰竭预后的关系:一项匹配加权队列分析

阅读:2

Abstract

AIMS: The prognostic significance of polycythemia in acute decompensated heart failure (ADHF) is unclear. This study aimed to evaluate the clinical profile and prognostic implications of polycythemia compared with anemia and normocythemia in patients hospitalized with ADHF. MATERIALS AND METHODS: We retrospectively analyzed adult patients hospitalized with ADHF between 2007 and 2017. Patients were categorized by hemoglobin according to World Health Organization criteria: anemic (<13 g/dL men, < 12 g/dL women), normocythemic, or polycythemic (>18.5 g/dL men, > 16.5 g/dL women). Mahalanobis distance matching (MDM; 1:3:3) balanced baseline characteristics, with outcomes compared for in-hospital mortality, 30-day readmission, and long-term survival. Entropy balancing (EBAL) served as sensitivity analysis in the full cohort. RESULTS: Of 8,332 patients, 5,615 (67.4%) were anemic, 2,639 (31.7%) normocythemic, and 78 (0.9%) polycythemic. Polycythemic patients were younger, predominantly male, and more likely to undergo coronary interventions and receive cardioprotective discharge medications. In the matched cohort (N = 546; 234 anemic, 234 normocythemic, 78 polycythemic), in-hospital mortality rates were similar (5.6%, 3.8%, 7.7%; p = 0.381). One-year mortality was highest in anemia (27.4%) vs. normocythemia (17.5%) and polycythemia (19.2%; p = 0.030). Five-year Kaplan–Meier survival was poorest in anemia, with overlapping curves for polycythemia and normocythemia (log-rank p = 0.027). Cox analysis (reference = normocythemia) showed higher mortality with anemia (HR 1.30, 95% CI 1.03–1.63) but not polycythemia (HR 0.90, 95% CI 0.64–1.27). Post-hoc pairwise log-rank tests (Bonferroni-corrected) confirmed no difference between polycythemia and normocythemia. EBAL-weighted analysis yielded consistent results (log-rank p < 0.001; anemia HR 1.76, 95% CI 1.61–1.92; polycythemia HR 1.14, 95% CI 0.83–1.57). CONCLUSIONS: Polycythemia is rare in hospitalized ADHF and, unlike anemia, is not associated with adverse short- or long-term outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。